Intranasal administration of small extracellular vesicles derived from mesenchymal stem cells ameliorated the

Anwar Fathollahi1, Seyed Mahmoud Hashemi1, Mostafa Haji Molla Hoseini1

  • 1Department of Immunology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Insights

Intranasal mesenchymal stem cell-derived small extracellular vesicles (MSC-SEVs) more effectively treat experimental autoimmune encephalomyelitis (EAE) in mice than MSCs. MSC-SEVs reduced clinical scores and CNS lesions by enhancing immunomodulatory responses.

Area of Science:

  • Neuroscience
  • Immunology
  • Regenerative Medicine

Background:

  • Experimental autoimmune encephalomyelitis (EAE) is a key mouse model for human multiple sclerosis.
  • EAE is characterized by CNS inflammation, demyelination, and motor coordination loss.

Purpose of the Study:

  • To evaluate the efficacy of intranasal mesenchymal stem cells (MSCs) and MSC-derived small extracellular vesicles (MSC-SEVs) in an EAE mouse model.
  • To assess the impact of these treatments on disease activity and antigen-specific immune responses.

Main Methods:

  • EAE mice received intranasal MSCs or MSC-SEVs at specific time points post-immunization.
  • Clinical symptoms and central nervous system (CNS) histological lesions were analyzed.
  • Splenocytes were assessed for T cell proliferation, regulatory T cell frequency, T-helper subset transcription factors, and cytokine levels.

Main Results:

  • Both MSCs and MSC-SEVs significantly reduced clinical scores and CNS lesions in EAE mice.
  • MSC-SEV treatment demonstrated superior efficacy in alleviating clinical symptoms compared to MSC treatment.
  • Treatments increased the frequency of regulatory T cells (Foxp3+ CD25+) and TGF-β levels; MSCs uniquely increased IL-10.

Conclusions:

  • Intranasal MSC-SEV administration is a more effective therapeutic strategy than MSCs for reducing EAE clinical scores and CNS pathology.
  • MSC-SEVs promote immunomodulatory responses, offering a promising therapeutic avenue for multiple sclerosis.

Related Concept Videos